A critical component of BioFIND is the standardized, longitudinal collection of biospecimens, which include plasma, blood, cerebrospinal fluid (CSF), DNA and RNA. An overview of available biospecimens from BioFIND is available on the MJFF website. A detailed inventory of the biospecimens is available through the BioFIND database and can be reviewed by investigators interested in incorporating BioFIND samples in their research. Please note that BioFIND samples can only be used for biomarker discovery and verification studies. Researchers interested in requesting specimens should review the BioFIND collection, processing and storage protocols for biospecimens, including the Biologics Manual.
Biospecimen Review Process
BioFIND samples are available through the Biospecimen Resource Allocation Committee (BRAC), a collaborative resource access program with NINDS, For additional information on submitting requests to access BioFIND samples to the BRAC, including upcoming submission deadlines, please visit the NINDS PD-BRAC webpage.
MJFF also funds promising projects that use BioFIND biospecimens. Submit a proposed budget using the proper template (Industry/For-Profit or Academic/Non-Profit) to email@example.com for review in parallel with the sample application submitted to NINDS.
The BioFIND study encourages interested investigators, whether associated with BioFIND or not, to apply for use of BioFIND biospecimens. Investigators should read all of the following information and refer to the Data & Specimens FAQ prior to submitting a request for samples to understand the process to apply for use of biospecimens (plasma, DNA, RNA, blood and CSF).
MJFF and the BioFIND Biospecimen Review Committee have entered into a partnership with the National Institute of Neurological Disorders and Stroke for accessing BioFIND biospecimens. All applications and proposals, and associated materials made available to reviewers (collectively, the "Confidential Information"), shall not be disclosed or discussed with any individual who has not been officially designated to participate in the review process, according to the terms of the National Institute of Health's Confidentiality and Non-Disclosure Rules.